Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …

Background Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are
requisite drivers of atopic dermatitis, evidenced by marked improvement after treatment with …

Background Systemic therapies are typically combined with topical corticosteroids for the
management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral Janus kinase (…

Background Current systemic treatments for children younger than 6 years with moderate-to-severe
atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Background The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens,
pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-…

Background Phase 3 trials have assessed efficacy of abrocitinib versus placebo in moderate-to-severe
atopic dermatitis, a common immunoinflammatory skin disease. This study …

Background Significant unmet need exists for long-term treatment of moderate to severe
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …

Background Primary (week 16) results from the ongoing phase 3, double-blind AD Up study
(NCT03568318) demonstrate a positive benefit–risk profile for upadacitinib + topical …

… Dr Soong received honoraria for participation in advisory boards and speaker bureaus
and research funding from Sanofi and Regeneron Pharmaceuticals Inc; received research …

Background For adolescent patients (aged ≥ 12 to < 18 years) with uncontrolled moderate-to-severe
atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in …